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Abstract
Background: Heart failure represents an important public health issue due to its high costs and growing incidence
worldwide. Evidence showing the regenerative potential of postmitotic heart tissue has suggested the existence of
endogenous cardiac stem cells in adult hearts. Cardiosphere-derived cells (CDC) constitute a candidate pool of such
cardiac stem cells. Previous studies using acute myocardial infarction (MI) models in rodents demonstrated an
improvement in cardiac function after cell therapy with CDC. We evaluated the therapeutic potential of CDC 60 days
after MI in a rat model.
Methods: CDC were obtained from human discarded myocardial tissue and rat hearts by enzymatic digestion with
collagenase II. At 10–15 days after isolation, small, round, phase-bright cells (PBCs) appeared on top of the adherent
fibroblast-like cells. The PBCs were collected and placed on a nonadherent plate for 2 days, where they formed
cardiospheres which were then transferred to adherent plates, giving rise to CDC. These CDC were characterized by
flow cytometry. Wistar rats were submitted to MI through permanent occlusion of the anterior descending coronary
artery. After 60 days, they were immunosuppressed with cyclosporine A during 10 days. On the third day, infarcted
animals were treated with 5 × 105 human CDC (hCDC) or placebo through intramyocardial injection guided by
echocardiogram. Another group of animals was treated with rat CDC (rCDC) without immunosuppression. hCDC and
rCDC were stably transduced with a viral construct expressing luciferase under control of a constitutive promoter. CDC
were then used in a bioluminescence assay. Functional parameters were evaluated by echocardiogram 90 and
120 days after MI and by Langendorff at 120 days.
Results: CDC had a predominantly mesenchymal phenotype. Cell tracking by bioluminescence demonstrated over
85% decrease in signal at 5–7 days after cell therapy. Cardiac function evaluation by echocardiography showed no
differences in ejection fraction, end-diastolic volume, or end-systolic volume between groups receiving human cells, rat
cells, or placebo. Hemodynamic analyses and infarct area quantification confirmed that there was no improvement in
cardiac remodeling after cell therapy with CDC.
Conclusion: Our study challenges the effectiveness of CDC in post-ischemic heart failure.
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Background
Heart failure (HF) represents an important public health
issue due to its high costs and growing incidence world-
wide. An ageing population and the increased survival
rate of patients suffering coronary events contribute to
aggravate this scenario [1]. Pharmacological therapy only
attenuates disease progression, and patients in advanced
stages of HF require heart transplantation, a treatment
option that is compromised by the shortage of organs.
Recent evidence showing the regenerative potential of
postmitotic heart tissue suggested the existence of a pool
of endogenous cardiac stem cells in adult hearts [2].
Since then, the scientific community has dedicated enor-
mous effort to the identification and isolation of these
cells [3–5], which may ultimately provide an alternative
therapy in the treatment of cardiac disease.
Cardiosphere-derived cells (CDC) constitute a candidate
pool of such cardiac stem cells. CDC comprise a heteroge-
neous population of cardiac cells, including a potentially
clonogenic stem cell subpopulation [6]. Several studies
have proposed that CDC have cardiomyogenic differenti-
ation potential in vitro [6–9]. Furthermore, infarcted ani-
mals treated with CDC showed improvement in cardiac
function, reduced scar size, and increased viability of the
myocardium when compared with placebo-treated
animals [6, 7, 10–12].
However, work utilizing lineage-tracing has demon-
strated that CDC failed to differentiate into cardiomyo-
cytes in vivo [13] and that cell therapy did not improve
cardiac function in murine infarct models [13, 14]. In
addition, other authors have questioned the differenti-
ation potential of CDC in vitro [15]. Despite existing
controversies about the therapeutic applicability of CDC
in animal models, these cells have already entered a
phase I clinical trial (CADUCEUS) [16]. Results from
the trial, after a 1-year follow-up, described a subtle
enhancement in the viability of cardiac muscle without
benefit to cardiac function [17]. A meta-analysis of
several cardiac clinical trials, including CADUCEUS,
showed that cell therapy provided no benefit in terms of
left ventricular function [18].
In light of this controversy, we evaluated the thera-
peutic potential of cell treatment with CDC in a rat
model of HF. We demonstrate that treatment with rat
CDC (rCDC) or human CDC (hCDC) did not improve
cardiac function in rats, and we propose that further
studies utilizing animal models are needed before this




Human myocardial tissue was obtained from the National
Institute of Cardiology (Brazil). Right atrial appendages,
routinely discarded from patients undergoing coronary ar-
tery bypass grafting (CABG), were collected and used for
cell isolation.
Animals
Two-month-old Wistar rats weighing ~200 g were used in
this study. The animals were maintained in cages with
food and water ad libitum and 12 h/12 h light/dark cycle.
Cell isolation
Briefly, human discarded myocardial tissue or rat hearts
were fractionated into small pieces (1 mm3) and digested
using collagenase type II (200 IU/ml). Samples were sub-
mitted to 5–7 cycles of digestion for 5 min at 37 °C
under gentle agitation. Cells were plated using the fol-
lowing culture medium: Ham’s F12 supplemented with
10% fetal bovine serum, 1% penicillin/streptomycin,
10 ng/ml of basic fibroblast growth factor (bFGF), 0.005
U/ml of erythropoietin, and 0.2 mM of glutathione.
Leukemia inhibitory factor (LIF) (10 ng/ml) was added
in the case of rat CDC. After ~15 days, phase-bright
cells (PBCs) were collected using phosphate buffer saline
(PBS) at 4 °C. PBCs were cultured using the same
medium on nonadherent plates, resulting in the forma-
tion of cardiospheres. After 2 days, cardiospheres were
collected and placed on adherent plates, giving rise to
CDC. Cells were expanded for at least three passages
before the experiments.
Flow cytometry
CDC were dissociated using a nonenzymatic solution and
blocked in PBS with 0.5% bovine serum albumin (BSA)
and Fc receptor blocking reagent (BD Biosciences) for
20 min at 4 °C. Cells were then stained, using the same so-
lution, with the following antibodies: hCDC—CD105,
CD90, CD73, CD44, CD166, CD54, CD146, CD45, CD19,
CD14, CD34, CD31, CD33, CD133, and CD117 (all from
BD Pharmingen); rCDC—CD90 (eBiosciences), CD29,
CD11b (BD Pharmingen), and CD45RA (Caltag). Data
were acquired in BD FACSCanto II or BD FACSAria IIu
and analyzed using FlowJo version X.
Echocardiography
Echocardiography was performed using the Vevo 770
High-Resolution Imaging System (VisualSonics) under
isoflurane anesthesia. Images were acquired in bidimen-
sional mode and analyzed by a blinded investigator. Left
ventricular end-diastolic volume (EDV), end-systolic vol-
ume (ESV), ejection fraction (EF), and fractional area
change (FAC) were calculated using Simpson’s method.
In brief, these parameters of cardiac function were
evaluated in a long parasternal axis view and four high-
temporal resolution B-mode short-axis images, taken at
different ventricular levels, as described previously [19].
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Examinations were performed before myocardial infarc-
tion (MI), 1 day before cell injection, and 60 and 90 days
after cell injection.
Myocardial infarction and cell injection
Animals were anesthetized with 80 mg/kg of ketamine
and 20 mg/kg of xylazine and placed under positive
pressure ventilation. After thoracotomy, the heart was
exposed and the left anterior descending (LAD)
coronary artery was ligated using 6–0 Prolene suture.
The chest was closed and the animals were carefully re-
moved from ventilation support. Sham-operated rats
were submitted to an identical procedure except for
LAD ligation. MI was confirmed by electrocardiography
(ECG). Infarcted animals were included in the study only
if the EF was below 45%.
Sixty days after MI, 5 × 105 CDC were delivered to the
myocardium using echocardiogram-guided injection.
Cells were injected using a 29 G needle into two regions
of the infarct border zone (2.5 × 105 cells/injection). The
placebo-treated group received only vehicle, which was
25% Matrigel® (Corning) in Ham’s F12. In the case of the
hCDC group and the corresponding placebo group, im-
munosuppression with cyclosporine A was started 2 days
before cell injection at a dose of 10 mg/kg/day [20] and
maintained for 10 days. In order to evaluate the quality
of cells before injections, viability was analyzed using
Trypan Blue Solution 0.4%. More than 95% of the cells
were viable before injection.
Bioluminescence
CDC were transduced with Luciferase 2 using a lenti-
viral vector as described previously [21]. To validate our
injection method, hCDC and rCDC were stably trans-
duced with luciferase 2 for in-vivo tracking. Cell tracking
of CDC-Luc2 was performed after intramyocardial injec-
tion guided by echocardiogram. The groups of animals
used for cardiac function evaluation received nontrans-
duced CDC instead. In-vivo bioluminescence studies
were conducted using the IVIS Lumina Imaging System
(Xenogen Corporation) after intraperitoneal injection of
150 mg/kg of D-Luciferin (Caliper Life Sciences).
Animals were imaged from the first day after CDC injec-
tion until the luminescent signal reached the lower limit
of detection for the equipment (600 counts). Analyses
were performed using Living Image software version 3.2.
Langendorff perfusion experiments
Animals received 5 IU/g of heparin by intraperitoneal in-
jection and were euthanized. Hearts were removed by ex-
tended sternotomy and cannulated through the ascending
aorta. The mechanical function was preserved using retro-
grade perfusion (at 10 ml/min with a peristaltic pump)
with Krebs–Henseleit solution (NaCl 118 mM, KCl
4.7 mM, NaHCO3 25 mM, KH2PO4 1.2 mM, MgSO4
1.2 mM, glucose 11 mM, and CaCl2 1.25 mM) in a modi-
fied Langendorff system. This physiological saline solution
was maintained at 37 °C and bubbled with carbogenic gas
mixture (95% O2, 5% CO2) for oxygenation and mainten-
ance of pH at 7.4. A small latex balloon attached to a pres-
sure transducer (MLT0380; ADInstruments) was inserted
into the left ventricle. The balloon volume was increased
until 0 mmHg of initial diastolic pressure was obtained
and then 20 μL of solution was added every 2 min. The
systolic and diastolic pressure records were digitized
through an analog–digital interface (PowerLab 400; ADIn-
struments) for offline analysis with Chart 4.0 software
(ADInstruments). Pressure versus volume curves were ob-
tained at varying loads in systole and diastole, and data were
analyzed by calculating the integral of the curves using
MATLAB software version 7.0.
Histomorphometry
Myocardial tissue was fixed in 4% paraformaldehyde for
24 h and paraffin-embedded. Six-micrometer sections
were stained with Sirius red and scanned to obtain
digital images of the entire heart. The percentage of left
ventricular area occupied by the infarct was calculated
by dividing the area stained in red (collagen fibers) by
the total area of the left ventricle. These areas were
quantified using Image Pro Plus software version 7.0.1 in
three regions of the heart (apex, middle portion, and
base). Results are shown as an average of the three
values.
Statistics
Data are shown as mean ± standard deviation. Echocardi-
ography data were analyzed using two-way ANOVA, while
Langendorff and histomorphometric data were analyzed
using one-way ANOVA. Bonferroni’s post test was applied
in both cases and p < 0.05 was considered significant.
Graph Pad Prism software version 6.0 was used for all
analyses.
Results
Isolation and characterization of human and rat CDC
We obtained CDC from human discarded myocardial tis-
sue and rat hearts. Between 10 and 15 days after cell isola-
tion from human and rat tissues, small, round, PBCs
appeared on top of adherent fibroblast-like cells derived
from explants. PBCs were collected and cultured for 2 days
on a nonadherent plate, where they formed cardiospheres
which were then transferred to adherent plates, giving rise
to CDC (Fig. 1a). We obtained cultures of explants de-
rived from human (Fig. 1b) and rat (Fig. 1e) tissues. Fig. 1c
and f show representative images of cardiospheres derived
from human and rat hearts, respectively. Both hCDC
(Fig. 1d) and rCDC (Fig. 1g) were successfully isolated and
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expanded until the third passage. hCDC expressed mesen-
chymal markers (CD105, CD73, CD90) and adhesion mol-
ecules (CD54, CD146, CD166) and showed low
expression of hematopoietic and endothelial markers
(CD45, CD14, CD19, CD34, CD31) when analyzed by flow
cytometry (Fig. 1h; n = 8). Similarly, rCDC expressed high
levels of mesenchymal markers (CD90.1, CD29), whereas
contamination by hematopoietic cells (CD45, CD11b) was
minimal (Fig. 1i; n = 4).
Transduction and tracking of CDC in infarcted
myocardium
Previous work has identified CDC as endogenous cardiac
progenitor cells with regenerative potential in models of
acute MI [6, 9, 22, 23]. We investigated this potential in a
rat chronic model by the injection of CDC 60 days post
MI. Figure 2a shows a rat infarcted heart 3 days after cell
therapy. Cells were present at the injection site. The bio-
luminescent signal of CDC-Luc2 was detected in the
thoracic region until day 7 post injection (Fig. 2d, e). Radi-
ance quantification demonstrated a 98.8% decrease in
mean bioluminescent signal at 5–7 days after injection of
hCDC in immunosuppressed rats (D1: 2.54 ± 2.52 × 105,
D3: 1.49 ± 1.15 × 105, D5–7: 3.21 ± 2.34 × 103p/sec/cm2/sr)
(Fig. 2b). Syngeneic rCDC presented an 87.2% reduction
in signal over the same period (D1: 4.63 ± 2.59 × 104, D3:
1.82 ± 1.04 × 104, D5–7: 5.95 ± 0.87 × 103p/sec/cm2/sr)
(Fig. 2c).
Cardiac functional evaluation post CDC treatment
To evaluate potential benefits of hCDC and rCDC ther-
apy, we performed in-vivo and ex-vivo analyses of car-
diac function. Figure 3 and Table 1 show the results of
echocardiographic examinations. We observed no differ-
ences in EDV (Fig. 3a), EF (Fig. 3b), ESV (Fig. 3c), or
FAC (Fig. 3d) between hCDC, rCDC, and placebo-
treated animals at all time points assessed. In these
animals, all tested parameters of cardiac function were
Fig. 1 Isolation and characterization of CDC. a Cardiac tissue was minced into small fragments and plated as explants. PBCs were collected and
cultured on nonadherent plates, forming cardiospheres. CDC were generated by transferring cardiospheres to adherent plates. Representative
images of human and rat explants (b, e), cardiospheres (c, f) and CDC (d, g). Surface molecule expression was characterized by flow cytometry in
hCDC (h) and rCDC (i). Note the large standard deviations for CD90 in both hCDC and rCDC, representing heterogeneous expression of this
molecule. hCDC human cardiosphere-derived cell, rCDC rat cardiosphere-derived cell
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significantly lower than those observed in sham-
operated animals.
To investigate the hemodynamic performance of iso-
lated hearts after cell therapy with CDC, we used a
modified Langendorff apparatus. The diastolic pressure
versus volume curves of infarcted animals shifted down-
wards when compared with the sham-operated group
(Fig. 3e). The same was observed for the systolic curve
(Fig. 3f ). The area under the curves was analyzed and no
differences were observed between placebo and cell-
treated animals (Fig. 3g, h).
To assess whether CDC treatment reduced the in-
farcted area, we performed morphometry with Sirius red
staining. Figure 3i shows the sham-operated heart with
viable muscle (light staining), whereas the infarcted heart
shows collagen fibers (dark staining), indicating scar
areas. The percentage of fibrosis was quantified in the
left ventricle after CDC cell therapy. Treated animals
(hCDC or rCDC) had no improvement in the amount of
viable cardiac muscle when compared with the placebo
group (Fig. 3j). The sham-operated group had signifi-
cantly less fibrotic tissue than the other groups.
Discussion
The present study evaluated the efficacy of late CDC
treatment in a rat model of HF. We chose to base our
work on a late treatment because it more closely resem-
bles the situation of most HF patients who develop the
disease over the course of many years. Moreover, in ad-
vanced stages there is no definitive therapy other than a
heart transplant. To date, the potential benefits of CDC
therapy had not been evaluated in a rat chronic model.
We reproduced in detail all of the steps described previ-
ously for stem cell isolation, identification, and injection.
Despite these efforts, we show that CDC therapy did not
improve cardiac function or reduce scarring in this ani-
mal model.
We isolated, expanded, and characterized CDC derived
from discarded human tissue or rat hearts using estab-
lished procedures [6, 9, 15]. Cells had the immunopheno-
typic profile described previously [6, 9] except for low c-
kit expression. The low expression of c-kit observed in
our work should not have posed a problem, because re-
cent work has shown no correlation between the presence
of c-kit and the regenerative efficacy of CDC [24]. Much
like the CDC used in previous studies [16, 17], our cells
expressed heterogeneous levels of CD90.
We injected CDC into the peri-infarcted area of the
myocardium, because this was the most common deliv-
ery route in rodent acute MI models treated with CDC
[6, 22, 24, 25]. Several authors have reported that a ma-
jority of injected cells die a few days after the procedure,
Fig. 2 CDC tracking by bioluminescence. a Ex-vivo image of a rat heart after echocardiography-guided intramyocardial injection of transduced
CDC. Signal is located on the border zone of the infarct. Quantification of luminescent signal in rats injected with hCDC (b) or rCDC (c).
d, e In-vivo cell tracking shows luminescent signal on the precordial region of infarcted rat. Luminescence was detected until 5–7 days
after injection. Color scales are shown in units of radiance, and quantification data are plotted on a log scale (Color figure online). hCDC human cardiosphere-
derived cell, rCDC rat cardiosphere-derived cell
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Fig. 3 Cardiac function evaluation after CDC therapy. a EDV, (b) EF, (c) ESV, and (d) FAC. Arrows, rats treated 1 day after the data were collected.
No differences were found when placebo, rCDC, and hCDC groups were compared. Sham-operated rats had significantly lower values of EDV
and ESV and higher values of EF and FAC when compared with the infarcted groups. Considering equal volumes, infarcted groups had lower
values of diastolic (e) and systolic (f) pressures when compared with sham-operated rats, suggesting cavity dilation and systolic dysfunction
respectively. The area under the diastolic (g) and systolic (h) curves (AUC) was calculated. There were no differences between placebo and cell-
treated groups. i Representative images of serial heart tissue slices stained by Sirius Red from sham, infarcted animals treated with CDC and
placebo. Fibrotic tissue is marked in red. j Quantification of fibrotic area showed a significant increase in infarcted groups when compared with
sham-operated rats. Shaded area represents values belonging to the sham group. No differences were observed between placebo, rCDC, and
hCDC groups. *p < 0.05 when comparing sham animals with infarcted animals (Color figure online). hCDC human cardiosphere-derived cell, rCDC
rat cardiosphere-derived cell
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and that 10% or fewer of the cells remain in the heart
[11]. Despite the chosen cell dose (2 million cells/kg of
body weight) being higher than the dose administered in
the CADUCEUS clinical trial (178,000–357,000 cells/kg
of body weight), our treatment resulted in low cell en-
graftment and retention levels, comparable with those
described previously [14]. To exclude the possibility that
the expression of luciferase 2 could alter the quality and
a putative therapeutic effect of CDC, the tracking assays
with transduced CDC were performed in a separate
group of animals. One limitation of our study was the
delivery of cells in only two injection sites. Although
injected cells are known to migrate from the site of in-
jection, we cannot exclude that multiple sites of injec-
tion are necessary to improve cardiac function.
Several groups have reported improvements in cardiac
function after CDC therapy in rodent models [6, 9, 22–26].
Acute treatment of small animals with CDC reduces scar
size [22, 25, 26], increases EF [6, 9, 23, 24, 26] and muscle
viability [9, 23], and decreases EDV as well as ESV [25]. On
the other hand, chronic treatment performed in large animal
models yielded subtle or negative results [10–12]. In 2009,
Marban’s group showed that placebo-treated and CDC-
treated pigs using the intracoronary route had similar values
of EF [10]. In a later study, the same group reported preser-
vation of function, but not improvement, when administer-
ing intramyocardial injection of CDC [11]. Takehara et al.
[12] achieved improved ventricular function in post-
MI pigs using a combination of bFGF gels and CDC,
an approach less translatable to the clinical setting;
however, administration of CDC to pigs without add-
itional growth factors resulted in only slight improve-
ment to the EF.
In preclinical experiments performed in small animals,
the best results have been obtained when cell therapy
has been administered immediately after coronary occlu-
sion, whereas the benefit obtained when using chronic
models in large animals has been quite modest. Despite
this limited success achieved in animal model studies,
CDC were administered to humans 2–4 months after
MI in the CADUCEUS phase I clinical trial. One year
after treatment, the trial reported MRI results showing a
decrease in scar tissue. Nevertheless, a recent meta-
analysis of several clinical trials reported that the CDC
used in CADUCEUS did not yield benefits in terms of
clinical events or changes in cardiac function [18]. Simi-
larly, all other cell therapies evaluated to date have been
of limited benefit to MI patients. The disappointing re-
sults from human trials clearly do not reflect the im-
provements observed in acute animal models.
Despite our efforts to closely reproduce best-practice
conditions for CDC therapy, evaluation of the animals
showed no differences in cardiac function between
groups receiving human cells, rat cells, or a placebo.
This lack of difference was also evident with regards to
scar size. Previous work in mice has similarly failed to
Table 1 Cardiac function of experimental groups
Experimental group
Parameter Time (days) Sham (n = 8) Placebo (n = 9) hCDC (n = 11) rCDC (n = 10)
Ejection fraction (%) –1 76.85 ± 4.24 75.50 ± 1.48 79.83 ± 5.34 72.97 ± 3.69
59 70.72 ± 2.08 32.88 ± 6.28* 31.48 ± 7.26* 30.39 ± 6.97*
90 69.33 ± 5.45 34.49 ± 9.48* 31.26 ± 7.66* 29.56 ± 7.59*
120 69.44 ± 5.36 34.62 ± 11.08* 30.89 ± 6.39* 28.58 ± 7.68*
End-diastolic volume (μl) –1 358.8 ± 68.61 383.7 ± 80.47 323.2 ± 39.71 357.7 ± 65.29
59 424.4 ± 97.15 643.1 ± 98.04* 712.3 ± 137.9* 656.8 ± 213.1*
90 438.7 ± 110.40 730.6 ± 172.90* 833.3 ± 234.3* 736.3 ± 259.8*
120 467.7 ± 108.2 736.20 ± 161.6* 830 ± 243.9* 840.2 ± 313.4*
End-systolic volume (μl) –1 80.91 ± 22.78 93.20 ± 25.63 69.52 ± 16.13 96.06 ± 18.68
59 121.4 ± 28.45 382.4 ± 105.2* 502 ± 135.8* 464.40 ± 179.3*
90 137.5 ± 50.67 488.80 ± 160.5* 609.2 ± 244.8* 525 ± 212.6*
120 142 ± 34.97 492.5 ± 163.6* 551 ± 214.9* 591.40 ± 271.3*
Fractional area change (%) –1 71.38 ± 11.53 67.38 ± 9.06 73.75 ± 8.34 66.05 ± 8.87
59 66.58 ± 7.23 30.22 ± 10.12* 25.15 ± 11.40* 24.90 ± 10.79*
90 63.95 ± 19.47 25.70 ± 9.56* 20.78 ± 10.16* 25.85 ± 8.36*
120 57.33 ± 11.30 27.71 ± 20.11* 29.65 ± 11.46* 25.47 ± 9.69*
Data presented as mean ± SD. Day –1 shows baseline values (before myocardial infarction) for all groups. Day 59 shows data 1 day before treatment with placebo,
hCDC, or rCDC
*p < 0.05 compared with sham-operated group
hCDC human cardiosphere-derived cell, rCDC rat cardiosphere-derived cell
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demonstrate any improvement after CDC treatment in
an acute MI model, in spite of achieving long-term en-
graftment. In that study, functional evaluations were per-
formed by several methods, such as echocardiogram,
hemodynamic analysis, MRI, and positron emission tom-
ography [14]. In addition, other groups have cast doubt
on whether CDC indeed constitute a source of stem
cells with cardiomyogenic potential [13, 15].
In light of these discrepant findings in animal models,
we suggest that it is time for a cautious step back. Pend-
ing issues—such as the differentiation potential of CDC,
the existence of CDC subpopulations, and new ap-
proaches to the isolation of cardiac stem cells
[27]—must be addressed before the potential therapeutic
effect of CDC in heart disease can be realized.
Conclusion
Treatment with CDC did not improve heart function or
prevent heart chamber dilatation in rats with MI and
cardiac remodeling. Our study challenges the effective-
ness of CDC in post-ischemic HF.
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